

# Breast Cancer Pathways: Endocrine Therapy for Recurrent or Metastatic Disease

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_ Pathology: \_\_\_\_\_

Stage: \_\_0 \_\_IA \_\_IB \_\_IIA \_\_IIB \_\_IIIA \_\_IIIB \_\_IIIC \_\_IV \_\_Recurrent

Line of Treatment: \_\_First Line \_\_Second Line \_\_Third Line \_\_Third Line+

## Biomarkers:

Estrogen Receptor (ER): \_\_Positive \_\_Negative

Menopausal Status: Pre / Peri / Post / NA (patient is male)

Progesterone Receptor (PR): \_\_Positive \_\_Negative

- Pre-menopausal only: Include ovarian suppression: Yes/No/Unknown

HER2 status: \_\_Positive \_\_Negative by \_\_ IHC \_\_FISH

## First line therapy (1<sup>st</sup> line) | Recurrent or Metastatic Disease | Hormone receptor positive

- Anastrozole (Arimidex)\*
- Fulvestrant, high dose (Faslodex)\*
- Letrozole (Femara)\*
- Letrozole (Femara) and palbociclib (Ibrance)\*
- Tamoxifen\*\*

## Second and subsequent lines of therapy (2nd line +) | Recurrent or Metastatic Disease | Hormone receptor positive

- Anastrozole (Arimidex)\*
- Exemestane (Aromasin)\*
- Fulvestrant, high dose\* (Faslodex)
- Fulvestrant (Faslodex) and palbociclib\* (Ibrance)
- Letrozole (Femara)\*
- Tamoxifen\*\*

## First and subsequent lines of therapy (1<sup>st</sup> line +) | Recurrent or Metastatic Disease | Hormone receptor positive | HER2 positive

- Anastrozole (Arimidex) and trastuzumab (Herceptin)\*
- Letrozole (Femara) and trastuzumab (Herceptin)\*

\* With ovarian suppression for premenopausal individuals. Ovarian suppression utilizes LHRH agonists given as monthly injections. 3-month depot dosing does not reliably suppress estrogen levels.

\*\* Tamoxifen is considered Pathway for premenopausal individuals with or without ovarian suppression

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

